Expert Opinion on Therapeutic Targets最新文献

Targeting the NLRP3 inflammasome with antibody-based Therapeutics for chronic neurodegenerative diseases. 靶向NLRP3炎性体的抗体治疗慢性神经退行性疾病

IF 4.4 2区医学

Expert Opinion on Therapeutic Targets Pub Date : 2026-05-09 DOI: 10.1080/14728222.2026.2671675

Jagdeep K Sandhu, Jamshid Tanha, Mehdi Arbabi-Ghahroudi

{"title":"Targeting the NLRP3 inflammasome with antibody-based Therapeutics for chronic neurodegenerative diseases.","authors":"Jagdeep K Sandhu, Jamshid Tanha, Mehdi Arbabi-Ghahroudi","doi":"10.1080/14728222.2026.2671675","DOIUrl":"https://doi.org/10.1080/14728222.2026.2671675","url":null,"abstract":"Introduction: The NLRP3 inflammasome is a central regulator of innate immunity that becomes aberrantly activated by amyloid-β, hyperphosphorylated tau, and α-synuclein aggregates in chronic neurodegenerative diseases such as Alzheimer's (AD) and Parkinson's disease (PD). Sustained activation drives neuroinflammation, synaptic dysfunction, and neuronal loss, making NLRP3 a compelling therapeutic target in chronic neurodegeneration.Topics covered: This review summarizes current insights into NLRP3 inflammasome biology in AD and PD, with emphasis on antibody-based interventions. Emerging delivery approaches, such as receptor-mediated transcytosis, nanoparticles, adeno-associated viral vectors, and magnetic resonance-guided focused ultrasound are also examined for their potential to enhance central nervous system (CNS) delivery of NLRP3-targeting antibodies.Expert opinion: Antibody-based inhibitors of the NLRP3 inflammasome offer high specificity and favorable safety profile compared with small-molecular-weight inhibitors; however, limited blood-brain barrier (BBB) penetration remains a major challenge. Advances in antibody engineering, modular bi-/multi-specific designs, and targeted CNS delivery platforms may soon enable the development of first-in-class antibodies capable of directly modulating neuroinflammation. To realize this potential, the field should prioritize: (1) developing BBB-penetrant antibody constructs; (2) integrating delivery technologies with target biology; and (3) accelerating translation toward first-in-human studies. Successful implementation could transform therapeutic strategies for AD and PD and extend antibody-based interventions across a broader spectrum of neuroinflammatory disorders.","PeriodicalId":12185,"journal":{"name":"Expert Opinion on Therapeutic Targets","volume":" ","pages":""},"PeriodicalIF":4.4,"publicationDate":"2026-05-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147863789","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

The role of human complement factor H in retinal immune response and the prospects for targeted therapy for age-related macular degeneration (AMD). 人补体因子H在视网膜免疫反应中的作用及年龄相关性黄斑变性（AMD）靶向治疗的前景

IF 4.4 2区医学

Expert Opinion on Therapeutic Targets Pub Date : 2026-05-08 DOI: 10.1080/14728222.2026.2671685

Anne Wolf, Thomas Clahsen, Thomas Langmann

引用次数: 0

Molecular-level host-microbe interactions: mechanisms, molecules, and modeling toward precision probiotics. 分子水平的宿主-微生物相互作用：机制、分子和精确益生菌的建模。

IF 4.4 2区医学

Expert Opinion on Therapeutic Targets Pub Date : 2026-05-08 DOI: 10.1080/14728222.2026.2671689

Huan Zhang, Shiqi Zhang, Jiangjiang Zhu

{"title":"Molecular-level host-microbe interactions: mechanisms, molecules, and modeling toward precision probiotics.","authors":"Huan Zhang, Shiqi Zhang, Jiangjiang Zhu","doi":"10.1080/14728222.2026.2671689","DOIUrl":"https://doi.org/10.1080/14728222.2026.2671689","url":null,"abstract":"Introduction: Advancing next-generation probiotics (NGPs) as precision therapeutics depends on a detailed understanding of host - microbe molecular interactions, as these organisms exert targeted effects through defined bioactive molecules rather than broad, nonspecific mechanisms. This review addresses the need to systematically organize emerging knowledge on microbe-derived molecules (MDMs) that underpin NGP efficacy.Areas covered: This narrative review summarizes recent discoveries of MDMs isolated from NGPs and classifies them based on three principal molecular interaction interfaces: protein - protein/peptide, protein - lipid or glycopeptide, and protein - metabolite interactions. We discuss how these molecules - encompassing proteins/peptides, lipids, glycoconjugates, and small metabolites - modulate host immune and metabolic pathways to maintain homeostasis. The literature was identified through targeted searches of recent peer-reviewed studies focusing on host - microbe molecular mechanisms and probiotic-derived bioactives. We also review the application of molecular docking, molecular dynamics simulations, and artificial intelligence - based tools in predicting host - microbe interactions and accelerating therapeutic discovery.Expert opinion: By integrating experimental insights with computational strategies, we propose a framework to guide the development of precision microbiome-based interventions tailored to specific diseases and individual microbiome profiles. These advances lay the foundation for rational design of targeted NGP therapies for metabolic, inflammatory, infectious, and neurodegenerative disorders.","PeriodicalId":12185,"journal":{"name":"Expert Opinion on Therapeutic Targets","volume":" ","pages":""},"PeriodicalIF":4.4,"publicationDate":"2026-05-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147835621","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Targeting the OPA1 pathway in autosomal dominant optic atrophy (ADOA): 25 years from gene discovery to therapeutic strategy. 针对常染色体显性视神经萎缩（ADOA）的OPA1通路：从基因发现到治疗策略的25年。

IF 4.4 2区医学

Expert Opinion on Therapeutic Targets Pub Date : 2026-05-08 DOI: 10.1080/14728222.2026.2671678

Marcel V Alavi

{"title":"Targeting the OPA1 pathway in autosomal dominant optic atrophy (ADOA): 25 years from gene discovery to therapeutic strategy.","authors":"Marcel V Alavi","doi":"10.1080/14728222.2026.2671678","DOIUrl":"https://doi.org/10.1080/14728222.2026.2671678","url":null,"abstract":"Introduction: Autosomal Dominant Optic Atrophy (ADOA) is a rare hereditary optic neuropathy primarily caused by OPA1 mutations. Retinal ganglion cell (RGC) loss results in variable visual impairments, occasionally accompanied by extra-ocular manifestations. ADOA also involves a developmental component consistent with OPA1's essential role in mitochondrial fusion, cristae organization, and quality control. As such, ADOA serves as a paradigm for studying mitochondrial contributions to neurodegeneration.Areas covered: This article provides a comprehensive overview of ADOA, covering genetic and clinical aspects while distinguishing between degenerative and developmental features of the pathology. The author examines OPA1 function and assesses emerging therapeutic strategies - ranging from gene augmentation and small-molecule therapeutics to alternative targets - before appraising translational challenges.Expert opinion: Antisense therapies targeting OPA1 haploinsufficiency are among the more advanced ADOA treatments currently under human safety evaluation, with other modalities following closely in development. However, the field still lacks robust clinical endpoints for the highly variable and slowly progressive phenotype. Furthermore, developmental RGC loss may limit therapeutic efficacy of late-stage interventions - a challenge compounded by the difficulty of early diagnosis. Nevertheless, the FDA's recent shift toward Bayesian statistical frameworks and the emergence of neuroprotective alternative targets are expected to streamline the clinical development for ADOA.","PeriodicalId":12185,"journal":{"name":"Expert Opinion on Therapeutic Targets","volume":" ","pages":""},"PeriodicalIF":4.4,"publicationDate":"2026-05-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147835640","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Relevance of lipid droplets in metabolic dysfunction-associated steatotic liver disease. 脂滴与代谢功能障碍相关的脂肪变性肝病的相关性

IF 4.4 2区医学

Expert Opinion on Therapeutic Targets Pub Date : 2026-05-08 DOI: 10.1080/14728222.2026.2671694

Ralf Weiskirchen, Amedeo Lonardo

{"title":"Relevance of lipid droplets in metabolic dysfunction-associated steatotic liver disease.","authors":"Ralf Weiskirchen, Amedeo Lonardo","doi":"10.1080/14728222.2026.2671694","DOIUrl":"https://doi.org/10.1080/14728222.2026.2671694","url":null,"abstract":"Introduction: Metabolic dysfunction-associated steatotic liver disease (MASLD) is the most common chronic liver disease globally, leading to cirrhosis, hepatocellular carcinoma, and increased liver-related mortality, along with extrahepatic risks. A hallmark of MASLD is excessive neutral lipid accumulation in hepatocytes as cytosolic lipid droplets (LDs), which are now recognized as dynamic organelles involved in lipid storage, energy metabolism, signaling, and stress responses. Understanding LD pathobiology in MASLD is vital for insights into disease mechanisms and targeted therapies.Areas covered: This review outlines current knowledge on LD biogenesis, growth, and turnover in hepatocytes and their disruption in MASLD. We discuss LDs' dual role as protective buffers against lipotoxicity and contributors to disease progression when lipid fluxes are altered. The involvement of LDs in non-parenchymal cells like hepatic stellate cells and macrophages in inflammation and fibrogenesis is examined. Human genetic studies linking LD-associated proteins (e.g. PNPLA3) to MASLD susceptibility are also discussed.Expert opinion: LDs are crucial in MASLD pathogenesis, integrating genetic factors with metabolic signals. Future therapies should focus on normalizing lipid flux and LD functions rather than indiscriminately depleting them to avoid disrupting protective storage mechanisms.","PeriodicalId":12185,"journal":{"name":"Expert Opinion on Therapeutic Targets","volume":" ","pages":""},"PeriodicalIF":4.4,"publicationDate":"2026-05-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147835597","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

An overview of outer membrane protein a (OmpA) as a therapeutic target for Acinetobacter baumannii infection. 外膜蛋白a （OmpA）作为鲍曼不动杆菌感染的治疗靶点的综述。

IF 4.4 2区医学

Expert Opinion on Therapeutic Targets Pub Date : 2026-05-08 DOI: 10.1080/14728222.2026.2671680

Md Minarul Islam, Man Hwan Oh, Woo Shik Shin, Je Chul Lee

{"title":"An overview of outer membrane protein a (OmpA) as a therapeutic target for Acinetobacter baumannii infection.","authors":"Md Minarul Islam, Man Hwan Oh, Woo Shik Shin, Je Chul Lee","doi":"10.1080/14728222.2026.2671680","DOIUrl":"https://doi.org/10.1080/14728222.2026.2671680","url":null,"abstract":"Introduction: The rapid dissemination of drug-resistant Acinetobacter baumannii strains has severely limited available therapeutic options, highlighting the urgent need for novel or alternative treatment strategies.Areas covered: Among the diverse virulence factors of A. baumannii, outer membrane protein A (AbOmpA) has emerged as a key pathogenic determinant. AbOmpA plays a multifaceted role in bacterial pathogenesis by mediating host cell adherence and invasion, biofilm formation, stress tolerance, modulation of host immune responses, and resistance to antimicrobial agents. Recent advances in high-throughput technologies, including proteomics, transcriptomics, and bioinformatics, have significantly expanded our understanding of the structure, function, and pathogenic roles of AbOmpA. Consequently, substantial research efforts have focused on the development of AbOmpA-targeted interventions, such as antimicrobial peptides, small molecule inhibitors, monoclonal antibodies, and vaccines. These approaches have demonstrated promising results in reducing bacterial virulence and disease severity, offering potential strategies to combat drug-resistant A. baumannii infections.Expert opinion: AbOmpA represents a highly promising therapeutic target for the treatment of A. baumannii infections due to its high abundance and conservation, its central role in bacterial pathogenesis, and its lack of homology with human proteins. However, further studies are required to overcome current limitations and to evaluate clinical applicability of AbOmpA-targeted therapies.","PeriodicalId":12185,"journal":{"name":"Expert Opinion on Therapeutic Targets","volume":" ","pages":""},"PeriodicalIF":4.4,"publicationDate":"2026-05-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147835554","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Molecular understanding for therapeutic targeting of hypoxia in breast cancer. 乳腺癌缺氧靶向治疗的分子认识。

IF 4.4 2区医学

Expert Opinion on Therapeutic Targets Pub Date : 2026-05-08 DOI: 10.1080/14728222.2026.2671683

Andrea Angeli, Claudiu T Supuran

{"title":"Molecular understanding for therapeutic targeting of hypoxia in breast cancer.","authors":"Andrea Angeli, Claudiu T Supuran","doi":"10.1080/14728222.2026.2671683","DOIUrl":"https://doi.org/10.1080/14728222.2026.2671683","url":null,"abstract":"Introduction: Breast cancer is one of the most widespread types of cancer, affecting millions of patients worldwide and although significant advances in its therapy have been achieved in the last decades, a large number of death still occur. Triple-negative breast cancer (TNBC) is the subtype associated with aggressive behavior, early metastasis, and limited therapeutic options, resulting in poor clinical outcomes for many affected patients. Many such tumors are frequently hypoxic.Areas covered: Hypoxia is a hallmark of solid tumors, including breast cancers. Molecular events triggered by hypoxia are orchestrated by hypoxia-inducible factors (HIFs), which regulate transcription of genes involved in cell survival, invasion, angiogenesis, and resistance to chemo- and radio-therapy. Apart HIF itself, other potential molecular targets such as prolyl-hydroxylases (PHD), von Hippel-Lindau protein (VHL), monocarboxylate transporters (MCTs), Na+ /H+ exchangers (NHEs), vacuolar ATPases (V-ATPase), anion exchangers (AEs), Na+ /HCO₃- co-transporters (NBCs), vascular endothelial growth factor (VEGF) and carbonic anhydrases were identified as being involved in tumorigenesis.Expert opinion: HIF-1α inhibitors (topotecan, digoxin, PX-478), hypoxia-activated prodrugs (evofosfamide, apaziquone, porfiromycin, tirapazamine, banoxantrone) and carbonic anhydrase IX/XII inhibitors (SLC-0111) are either used clinically or in clinical development for the management of hypoxic breast cancers.","PeriodicalId":12185,"journal":{"name":"Expert Opinion on Therapeutic Targets","volume":" ","pages":""},"PeriodicalIF":4.4,"publicationDate":"2026-05-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147835612","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Advancing our understanding of molecular targets for hepatic ischemia-reperfusion injury therapy. 推进我们对肝缺血再灌注损伤治疗分子靶点的认识。

IF 4.4 2区医学

Expert Opinion on Therapeutic Targets Pub Date : 2026-05-07 DOI: 10.1080/14728222.2026.2671677

Siyuan Yao, Jerzy W Kupiec-Weglinski

{"title":"Advancing our understanding of molecular targets for hepatic ischemia-reperfusion injury therapy.","authors":"Siyuan Yao, Jerzy W Kupiec-Weglinski","doi":"10.1080/14728222.2026.2671677","DOIUrl":"https://doi.org/10.1080/14728222.2026.2671677","url":null,"abstract":"Introduction: Hepatic ischemia-reperfusion injury (IRI) remains a challenge in liver transplantation (LT), particularly with the increasing utilization of marginal grafts. Driven by ischemic stress and hemodynamic instability, IRI triggers intricate inflammatory responses. There is an urgent need to address this challenge by translating mechanistic insights into clinical practice.Areas covered: This review examines IRI mechanisms across diverse cell types and assesses new therapeutic targets identified in recent preclinical and clinical research. It also addresses the implications of IRI in the context of pre-transplant machine perfusion (MP), highlighting approaches to reduce injury and improve graft function, especially in marginal or high-risk liver grafts.Expert opinion: Hepatic IRI research is evolving despite historical challenges like species variability and reliance on rodent models. Advances in MP and studies on discarded human livers now provide clinically relevant validation platforms. This progress shifts our focus toward a vital goal: salvaging marginal grafts to alleviate the global donor organ shortage. Because the intricate nature of IRI limits single-pathway therapies, comprehensive strategies targeting mitochondria, reactive oxygen species, and hepatoprotection are gaining traction. Additionally, basic research should harness big data to identify therapeutic targets that are both highly translatable and reliable, ensuring more effective clinical solutions.","PeriodicalId":12185,"journal":{"name":"Expert Opinion on Therapeutic Targets","volume":" ","pages":""},"PeriodicalIF":4.4,"publicationDate":"2026-05-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147835548","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

P2 receptors as emerging therapeutic targets in neglected parasitic diseases. P2受体作为被忽视的寄生虫病的新治疗靶点

IF 4.4 2区医学

Expert Opinion on Therapeutic Targets Pub Date : 2026-05-07 DOI: 10.1080/14728222.2026.2671682

Mariana M Chaves, Nayara Carvalho-Barbosa, Luiz Eduardo Baggio Savio, Robson Coutinho-Silva

{"title":"P2 receptors as emerging therapeutic targets in neglected parasitic diseases.","authors":"Mariana M Chaves, Nayara Carvalho-Barbosa, Luiz Eduardo Baggio Savio, Robson Coutinho-Silva","doi":"10.1080/14728222.2026.2671682","DOIUrl":"https://doi.org/10.1080/14728222.2026.2671682","url":null,"abstract":"Introduction: Despite sustained control efforts, neglected parasitic diseases, such as malaria, leishmaniasis, Chagas disease, schistosomiasis, and toxoplasmosis, continue to exert a substantial global burden, driven by high prevalence, restricted therapeutic options, drug-associated toxicity, and the progressive emergence of resistance.Areas covered: Accumulating evidence has positioned purinergic signaling as a central regulatory axis in host - parasite interactions, in which P2 receptors are inherently ambiguous, as their signaling can promote either protective or detrimental immune responses depending on the cellular and microenvironmental context. The activation of the P2×7 receptor encourages inflammasome assembly, proinflammatory cytokine release, and microbicidal activity, aiding parasite elimination, though it can also lead to tissue damage in certain scenarios. Moreover, P2Y receptors regulate immune cell recruitment, cell death, and fibrotic responses, thereby influencing infection progression. Altered expression and function of P2 receptors across parasitic diseases highlight their crucial role in pathogenesis and immune regulation.Expert opinion: This review compiles current evidence supporting P2 receptors as viable therapeutic targets and emphasizes their potential to guide the development of safer and more effective interventions against tropical parasitic diseases.","PeriodicalId":12185,"journal":{"name":"Expert Opinion on Therapeutic Targets","volume":" ","pages":""},"PeriodicalIF":4.4,"publicationDate":"2026-05-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147835608","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Targets of senescence in cardiac muscle: insights for regenerative treatments in the aged heart. 心肌衰老的目标：对老年心脏再生治疗的见解。

IF 4.4 2区医学

Expert Opinion on Therapeutic Targets Pub Date : 2026-05-07 DOI: 10.1080/14728222.2026.2671690

Georgina M Ellison-Hughes, Daniele Torella

{"title":"Targets of senescence in cardiac muscle: insights for regenerative treatments in the aged heart.","authors":"Georgina M Ellison-Hughes, Daniele Torella","doi":"10.1080/14728222.2026.2671690","DOIUrl":"https://doi.org/10.1080/14728222.2026.2671690","url":null,"abstract":"Introduction: Despite considerable investment of time and funding, advancement in cardiac regenerative therapies has been slow. Results of large animal and human studies have failed to live up to the expectations of the positive pre-clinical animal studies. There are many reasons to explain the discrepancies, however a key factor is that patients in need of regenerative therapies are mostly aged, being 70 years and older.Areas covered: The aging heart undergoes structural and functional changes due to biological mechanisms associated with aging. Of these, increased senescent cell burden, inflammaging, and metabolic dysfunction are particularly relevant to the heart. Targeting of senescent cells using senotherapeutics alleviates the detrimental features of cardiac aging, including myocardial dysfunction, hypertrophy and fibrosis, and activates endogenous cardiac regeneration.Expert opinion: The future of myocardial regenerative therapies relies on us dissecting the pathways that regulate the phenotype of the aged heart. Whether these therapies are gene, cell or pharmacological, they must be tested in pre-clinical models and experimental medicine studies which reflect the patient population they are designed to treat. Senotherapeutics hold enormous promise as adjuncts to regenerative therapies by rejuvenating the tissue microenvironment and enhancing the resilience of the aging heart.","PeriodicalId":12185,"journal":{"name":"Expert Opinion on Therapeutic Targets","volume":" ","pages":""},"PeriodicalIF":4.4,"publicationDate":"2026-05-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147835571","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0